Loading...
NPI 1134538713 · Raleigh, NC · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Mako Medical Laboratories, LLC is a clinical medical laboratory provider located in Raleigh, North Carolina. This profile covers 271 Medicare and 270 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Mako Medical Laboratories, LLC |
| Address | 8461 Garvey Dr |
| City | Raleigh |
| State | NC |
| ZIP | 27616 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | August 7, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $97.9M |
| Medicare | $11.2M |
MAKO MEDICAL LABORATORIES, LLC has been an active NPI-enumerated clinical medical laboratory since 2014-08-07 (about ~12 years), indicating an established operating tenure likely supporting both diagnostic and large-scale testing services across payers.
Medicaid dominates this lab’s lifetime payer mix by scale: total Medicaid revenue is $97.9M versus total Medicare revenue of $11.2M, meaning the provider operates primarily as a Medicaid-serving lab rather than a Medicare-focused one.
Medicare revenue is concentrated: the precomputed top 3 Medicare codes account for 24.5% of total Medicare revenue, with high-volume specimen collection and core chemistry/microbiology panels such as 36415, 80053, and immunoassays like 84443 and 82306 appearing among top contributors, consistent with a high-throughput clinical laboratory model that handles routine and specialty tests.
Medicaid revenue is even more concentrated in definitive and presumptive drug testing and high-throughput infectious testing: the precomputed top 3 Medicaid codes represent 54.6% of Medicaid revenue, and the single code G0482 alone is $20.8M (23.0% of Medicaid revenue) where the provider ranks #1 in-state and is an extreme outlier—this indicates a dominant state-level position in multi-class definitive drug testing.
Competitive standing: nationally on Medicare the provider shows multiple extreme outlier positions (100th percentile) or very high percentiles for common lab tests — examples include 82306, 36415, 80053, 84443, 80048, 87635 — which signals unusually large testing volumes relative to national peers and suggests substantial national-level throughput for both routine and molecular diagnostics.
On Medicaid, the provider’s rankings are concentrated at the top in-state for substance testing and high-volume SARS-CoV-2 and presumptive drug testing (e.g., G0482 ranks #1 of 63, G0483 and G0480 rank in the top 3 of many peer sets, U0003 ranks #4 of 158), indicating the lab is a major statewide provider for substance-testing services and high-throughput infectious disease testing.
Service-line implications: the code mix across both payers (heavy presence of G0480–G0483, 80307, U0003, U0005, and panels like 80053/80061) points to an operational focus combining large-scale toxicology/definitive drug testing, routine clinical panels (CMP, lipid, CBC), and molecular infectious testing (COVID-19 and multiplex respiratory assays), implying investments in GC/MS–LC/MS platforms and high-throughput NAAT workflows.
Statistical outlier characterization: many top Medicare codes are labeled “extreme outlier” or “100th percentile” (e.g., 82306, 36415, 80053, 85025, 83036), and multiple Medicaid codes are described as “extreme outlier” or “notably above typical state volume” (e.g., G0482, G0483, 80307, G0480), reinforcing that this provider’s volumes for both routine and specialized tests are unusually large relative to peers and concentrated in a few high-volume services.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
271 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | 853,420 | $1 | $853.4K |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 25,730 | $30 | $746.2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4,440 | $150 | $679.9K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 83,890 | $10 | $671.1K |
| 84443 | The lab analyst performs a test to measure the amount of thyroid–stimulating hormone (TSH), a hormone produced in the pituitary gland that helps regulate thyroid function. The typical specimen is the… | 39,370 | $20 | $629.9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5,570 | $110 | $623.4K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 57,860 | $10 | $578.6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 7,350 | $70 | $544K |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 40,990 | $10 | $532.8K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 7,050 | $60 | $430.2K |
Showing 1–10 of 271
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 271 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
271 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| U0003 | 3 | 10 | 90 | $70 | $463.6K |
| 83704 | 4 | 10 | 290 | $30 | $379.7K |
| 87536 | 2 | 10 | 60 | $80 | $328.6K |
| G0483 | 6 | 80 | 70 | $240 | $291.1K |
| P9603 | 1 | 10 | 66,050 | $1 | $236.5K |
| 87799 | 2 | 10 | 5,480 | $40 | $228.3K |
| U0005 | 4 | 20 | 310 | $20 | $158.1K |
| 82088 | 3 | 10 | 580 | $40 | $125.3K |
| 83993 | 4 | 10 | 2,830 | $20 | $120.4K |
| 83013 | 4 | 10 | 840 | $70 | $115.9K |
Showing 1–10 of 271
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
270 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 203,440 | $100 | $20.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 114,320 | $140 | $15.7M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 314,470 | $40 | $12.9M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 221,040 | $50 | $11.5M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 201,490 | $50 | $10.5M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 74,720 | $60 | $4.2M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 18,170 | $110 | $2M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 85,950 | $20 | $1.4M |
| 82306 | The lab analyst measures the vitamin D level, typically on a serum specimen. This analyte, commonly known as vitamin D, is not really a vitamin, but is an important steroid hormone that is produced… | 64,650 | $20 | $1.3M |
| 80061 | The lab analyst performs a lipid panel test in which he measures the blood level of cholesterol and fats called triglycerides in the blood. | 108,600 | $10 | $977.4K |
Showing 1–10 of 270
How this provider's Medicaid billing volume and revenue compare to other North Carolina providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. North Carolina median
270 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 4 | 160 | 840 | $70 | $2.3M |
| 87902 | The lab analyst performs the technical lab test to analyze the specific genotype by nucleic acid of a specimen containing hepatitis C virus. | 5 | 10 | 1,360 | $150 | $1.8M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 110 | 1,450 | $110 | $1.7M |
| 87801 | The lab analyst performs a test for multiple infectious agents using amplified nucleic acid probe technique. | 24 | 40 | 480 | $40 | $1.4M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 5 | 80 | 420 | $30 | $1.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 60 | 1,640 | $100 | $940.2K |
| 86003 | The lab analyst performs the technical lab test to analyze a specimen such as serum for allergen–specific immunoglobulin E (IgE), using a crude allergen extract. The test result is quantitative or… | 9 | 40 | 220 | $60 | $920.5K |
| 87661 | The lab analyst performs a test for Trichomonas vaginalis using nucleic acid amplified probe technique. | 5 | 70 | 280 | $20 | $896.7K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 4 | 360 | 1,830 | $40 | $819.8K |
| 87507 | The lab analyst performs a test to detect 12 to 25 types or subtypes of a pathogen, such as Clostridium difficile, E. coli, Salmonella, Shigella, norovirus, Giardia, that affects the gastrointestinal… | 5 | 10 | 250 | $160 | $731K |
Showing 1–10 of 270
Other providers in the same ZIP code as Mako Medical Laboratories, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Yelvertons Enrichment Services Inc | NC | Community/Behavioral Health Agency | $0 | $24.1M |
| Michael Altenburg | NC | Neuroradiology Physician | $195.4K | $0 |
| Joel Blass | NC | Internal Medicine Physician | $96.4K | $0 |
| Jeffrey Handschumacher | NC | Optometrist | $12.1K | $78K |
| Jason Simpson | NC | Anesthesiology Physician | $17.5K | $0 |
| Anthony Carden | NC | Anesthesiologist Assistant | $13.1K | $0 |
| Tyrone Brown | NC | Certified Registered Nurse Anesthetist | $7.8K | $0 |
| Marc Douek | NC | Physical Therapist | $860 | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.